Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder

Bibliography

• Abrams P, Cardozo L, Fall M, The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Kannan H, Radican L, Turpin RS, Bolge SC. Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence. Urology 2009;74:34-8
   PubMed Web of Science ®Google Scholar
• Coyne K, Payne C, Bhattacharyya S, The impact of urinary urgency and frequency on health related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:451-9
   Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Wennberg AL, Molander U, Fall M, A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol 2009;55:783-91
   PubMed Web of Science ®Google Scholar
• Thomas L, Culley EJ. Overactive bladder disease: the urge for better therapies. J Manag Care Pharm 2008;14:381-6
   PubMed Web of Science ®Google Scholar
• D'Souza AO, Smith MJ, Miller L-A, Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14:291-301
   PubMed Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505
   PubMed Web of Science ®Google Scholar
• Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;348:383-6
   PubMed Web of Science ®Google Scholar
• Basra RK, Wagg A, Chapple C, A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008;102:774-9
   PubMed Web of Science ®Google Scholar
• Gelnique® prescribing information. Available from: http://pi.watson.com/data_stream.asp?product_group=1634&p=pi&language=E
   Google Scholar
• Andersson KE, Chapple CR, Cardozo L, Pharmacological treatment of urinary incontinence. 4th edition. In: Abrams P, Cardozo L, Khoury S, Wein A, editors, Incontinence, Paris: Health Publication Ltd; 2005. pp. 809-54
   Google Scholar
• Chapple CR, Khullar V, Gabriel Z, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Staskin DR. Transdermal systems for overactive bladder: principles and practice. Rev Urol 2003;5:(Suppl 8):S26-30
   PubMedGoogle Scholar
• Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
   PubMed Web of Science ®Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55(Suppl 5A):33-46
   PubMedGoogle Scholar
• Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int 2009;103:1324-33
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol 2003;43:1-5
   PubMed Web of Science ®Google Scholar
• Masuda H, Kim YT, Tyagi S, Local effects of antimuscarinics. Urol Clin North Am 2006;33:511-8, ix-x
   PubMed Web of Science ®Google Scholar
• Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997;157:1093-7
   PubMed Web of Science ®Google Scholar
• Oki T, Toma-Okura A, Yamada S. Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther 2006;316:1137-45
   PubMed Web of Science ®Google Scholar
• Starkman JS, Dmochowski RR. Management of overactive bladder with transdermal oxybutynin. Rev Urol 2006;8:93-103
   PubMedGoogle Scholar
• Douchamps J, Derenne F, Stockis A, The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-20
   PubMed Web of Science ®Google Scholar
• Appell RA, Chancellor MB, Zobrist RH, Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003;78:696-702
   PubMed Web of Science ®Google Scholar
• Zobrist RH, Schmid B, Feick A, Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001;18:1029-34
   PubMed Web of Science ®Google Scholar
• Hughes KM, Lang JCT, Lazare R, Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 2009;22:859-69
   Google Scholar
• Sahai A, Mallina R, Dowson C, Evolution of transdermal oxybutynin in the treatment of overactive bladder. Int J Clin Pract 2008;62:167-70
   PubMed Web of Science ®Google Scholar
• Zobrist RH, Quan D, Thomas HM, Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003;20:103-9
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW; for the Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D, Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007;99:836-44
   PubMed Web of Science ®Google Scholar
• Roberts MS, Cross SE, Anissimov YG. Factors affecting the formation of a skin reservoir for topically applied solutes. Skin Pharmacol Physiol 2004;17:3-16
   PubMed Web of Science ®Google Scholar
• Caramelli KE, Staskin DR, Volinn W. Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system [abstract]. J Urol 2008;179(suppl):513-4
   PubMedGoogle Scholar
• Hayashi N, Kamada T, Sato N, Inhibition of cytochrome P-450-dependent mixed function oxidation by ethanol. Dig Dis Sci 1985;30:334-9
   PubMedGoogle Scholar
• Kao J, Carver MP. Cutaneous metabolism of xenobiotics. Drug Metab Rev 1990;22:363-410
   PubMed Web of Science ®Google Scholar
• Caramelli KE, Thomas H, Stanworth S, Hoel G. Steady-state bioavailability of oxybutynin topical gel at 3 different application sites. Poster presented at: Annual Senior Care Pharmacy Meeting of the American Society of Consultant Pharmacists; 19-22 November 2008; New Orleans, LA
   Google Scholar
• Caramelli KE, Stanworth S, Volinn W, Hoel G. Pharmacokinetics of oxybutynin topical gel: effects of showering, sunscreen application, and person-to-person transference. Poster presented at: Annual Meeting of the American College of Clinical Pharmacy; 19-22 October 2008; Louisville, KY
   Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo-controlled, multicenter study. J Urol 2009;181:1764-72
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Staskin DR, MacDiarmid SA, Efficacy and safety of oxybutynin chloride topical gel in women with overactive bladder: a randomized, placebo-controlled, double-blind study [abstract]. J Urol 2009;181:589
   Web of Science ®Google Scholar
• Newman DK, Sand PK, Caramelli KE, Quality of life in a randomized, double-blind, placebo-controlled study of oxybutynin chloride topical gel treatment of patients with overactive bladder. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual lnternational Meeting; 16-20 May 2009; Orlando, FL
   Google Scholar
• Berger RS, Bowman JP. A reappraisal of the 21-day cumulative irritation test in man. J Toxicol Cutan Ocul Toxicol 1982;1:109-15
   Google Scholar
• Dmochowski R, Staskin D, Kell S. Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. Exp Opin Pharmacother 2002;3:443-54
   PubMedGoogle Scholar
• Dmochowski RR, Sand PK, Zinner NR, ; for the Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Nitti V, Staskin D, Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005;23:263-70
   PubMed Web of Science ®Google Scholar
• Oxytrol® prescribing information. Available from: http://pi.watson.com/data_stream.asp?product_group=1295&p=pi&language=E
   Google Scholar
• Kay GG, Staskin DR, MacDiarmid SA, Are the effects of oxybutynin on cognition dependent upon the route of administration – topical or oral? A double-blind placebo-controlled study employing sensitive cognitive and psychomotor testing. Poster presented at: 39th Annual Meeting of the International Continence Society; September 29– October 3 2009; San Francisco, CA
   Google Scholar
• Milsom I, Irwin DE. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. Eur Urol 2007;6:4-9
   Web of Science ®Google Scholar
• Roehrborn CG, Abrams P, Rovner ES, Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006;97:1003-6
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Dmochowski R, Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328-32
   PubMed Web of Science ®Google Scholar
• Staskin DR, Rosenberg MT, Dahl NV, Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2007;6:27-38
   Google Scholar